CATX Stock Overview
Develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Perspective Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.35 |
| 52 Week High | US$19.05 |
| 52 Week Low | US$1.60 |
| Beta | 1.13 |
| 1 Month Change | 20.51% |
| 3 Month Change | -27.47% |
| 1 Year Change | -86.57% |
| 3 Year Change | -19.22% |
| 5 Year Change | -68.57% |
| Change since IPO | -76.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| CATX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.2% | -9.0% | -0.3% |
| 1Y | -86.6% | -15.2% | 8.0% |
Return vs Industry: CATX underperformed the US Biotechs industry which returned -15.2% over the past year.
Return vs Market: CATX underperformed the US Market which returned 8% over the past year.
Price Volatility
| CATX volatility | |
|---|---|
| CATX Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: CATX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CATX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 139 | Thijs Spoor | www.perspectivetherapeutics.com |
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.
Perspective Therapeutics, Inc. Fundamentals Summary
| CATX fundamental statistics | |
|---|---|
| Market cap | US$174.02m |
| Earnings (TTM) | -US$78.33m |
| Revenue (TTM) | US$1.45m |
119.7x
P/S Ratio-2.2x
P/E RatioIs CATX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CATX income statement (TTM) | |
|---|---|
| Revenue | US$1.45m |
| Cost of Revenue | US$39.43m |
| Gross Profit | -US$37.97m |
| Other Expenses | US$40.36m |
| Earnings | -US$78.33m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 12, 2025
| Earnings per share (EPS) | -1.06 |
| Gross Margin | -2,611.76% |
| Net Profit Margin | -5,387.21% |
| Debt/Equity Ratio | 0.6% |
How did CATX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 01:48 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Perspective Therapeutics, Inc. is covered by 16 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Alec Stranahan | BofA Global Research |
| Yuan Zhi | B. Riley Securities, Inc. |